22.02.2020 11:43:06
|
FDA Approves New LDL-C Lowering Drug, NEXLETOL
(RTTNews) - The FDA has approved Esperion Therapeutics Inc's (ESPR) NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL cholesterol (LDL-C)-lowering medicine.
The company stated that the NEXLETOL is for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
NEXLETOL will be commercially available in the U.S., by prescription only, on March 30, 2020, the company specified.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Esperion Therapeutics Incmehr Nachrichten
06.11.24 |
Ausblick: Esperion Therapeutics zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Esperion Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Esperion Therapeutics Inc | 1,57 | -4,87% |
|